Efficacy of Omalizumab in Indolent Systemic Mastocytosis

Background. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficac...

Full description

Saved in:
Bibliographic Details
Main Authors: Calum Slapnicar, Martina Trinkaus, Lisa Hicks, Peter Vadas
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2019/3787586
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561992932524032
author Calum Slapnicar
Martina Trinkaus
Lisa Hicks
Peter Vadas
author_facet Calum Slapnicar
Martina Trinkaus
Lisa Hicks
Peter Vadas
author_sort Calum Slapnicar
collection DOAJ
description Background. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficacy of SM is limited. Methods. A retrospective analysis of 6 patients diagnosed with indolent SM treated with omalizumab at St. Michael’s Hospital between 2009 and 2018 is described. Reported frequency of anaphylaxis, baseline and follow-up tryptase levels, and SM-related symptoms were captured to measure the control of the disease. Results. Of the 5 patients who had experienced unprovoked anaphylaxis prior to treatment with omalizumab, 3 had no further episodes of anaphylaxis following initiation of omalizumab, while the remaining 2 patients had milder multisystem reactions. Significant improvement in cutaneous symptoms was also observed. Conclusion. These data suggest that omalizumab provides benefit to patients with SM who remain highly symptomatic in spite of treatment with conventional therapies.
format Article
id doaj-art-915b2fac541d4ef3878b62ab0516458c
institution Kabale University
issn 2090-6560
2090-6579
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Case Reports in Hematology
spelling doaj-art-915b2fac541d4ef3878b62ab0516458c2025-02-03T01:23:45ZengWileyCase Reports in Hematology2090-65602090-65792019-01-01201910.1155/2019/37875863787586Efficacy of Omalizumab in Indolent Systemic MastocytosisCalum Slapnicar0Martina Trinkaus1Lisa Hicks2Peter Vadas3Division of Allergy and Clinical Immunology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaDivision of Hematology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaDivision of Hematology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaDivision of Allergy and Clinical Immunology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaBackground. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficacy of SM is limited. Methods. A retrospective analysis of 6 patients diagnosed with indolent SM treated with omalizumab at St. Michael’s Hospital between 2009 and 2018 is described. Reported frequency of anaphylaxis, baseline and follow-up tryptase levels, and SM-related symptoms were captured to measure the control of the disease. Results. Of the 5 patients who had experienced unprovoked anaphylaxis prior to treatment with omalizumab, 3 had no further episodes of anaphylaxis following initiation of omalizumab, while the remaining 2 patients had milder multisystem reactions. Significant improvement in cutaneous symptoms was also observed. Conclusion. These data suggest that omalizumab provides benefit to patients with SM who remain highly symptomatic in spite of treatment with conventional therapies.http://dx.doi.org/10.1155/2019/3787586
spellingShingle Calum Slapnicar
Martina Trinkaus
Lisa Hicks
Peter Vadas
Efficacy of Omalizumab in Indolent Systemic Mastocytosis
Case Reports in Hematology
title Efficacy of Omalizumab in Indolent Systemic Mastocytosis
title_full Efficacy of Omalizumab in Indolent Systemic Mastocytosis
title_fullStr Efficacy of Omalizumab in Indolent Systemic Mastocytosis
title_full_unstemmed Efficacy of Omalizumab in Indolent Systemic Mastocytosis
title_short Efficacy of Omalizumab in Indolent Systemic Mastocytosis
title_sort efficacy of omalizumab in indolent systemic mastocytosis
url http://dx.doi.org/10.1155/2019/3787586
work_keys_str_mv AT calumslapnicar efficacyofomalizumabinindolentsystemicmastocytosis
AT martinatrinkaus efficacyofomalizumabinindolentsystemicmastocytosis
AT lisahicks efficacyofomalizumabinindolentsystemicmastocytosis
AT petervadas efficacyofomalizumabinindolentsystemicmastocytosis